Tracon reports Phase Ib data for carotuximab in NSCLC

In October, Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported data from 8 evaluable patients with stage IV non-squamous non-small cell lung cancer (NSCLC) in a Phase Ib trial showing that carotuximab (IV TRC105) in combination with paclitaxel/carboplatin and Avastin bevacizumab led to partial responses in 37% of patients, including 1 patient who had an 81% reduction in tumor volume. The combination led to median progression-free survival (PFS), a secondary endpoint, of 6.54 months.

No dose-limiting toxicities were observed. Data were presented at the International Association for the Study of Lung Cancer (IASLC) meeting in Yokohama...